WASHINGTON — Rep. Elijah Cummings (D-Md.) has always been outspoken on the issue of drug pricing, even wrangling a meeting with President Trump in March to discuss how to reduce costs for Americans struggling with the cost of their prescriptions.
Cummings, who recently returned to Capitol Hill after recuperating from heart surgery, used a decidedly different medium — one preferred by the President — on Thursday in resurfacing the issue.
US government holds the patent to #Zinbryta (treats #MS) and licenses it to @biogen. You can make a deal to lower the price now!
— Elijah E. Cummings (@RepCummings) September 28, 2017
The messages came weeks after Knowledge Ecology International wrote a letter to top Trump advisors and Health and Human Services Secretary Tom Price, encouraging them to take action to cap the cost of Zinbryta, a multiple sclerosis drug priced by Biogen at nearly $90,000 annually.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect